My expertise is blood cancer, specifically multiple myeloma (bone marrow cancer). But I follow therapy innovation for other blood cancers, too; often the same drugs–sometimes in a different combination or with a tweak here or there–work for myeloma, too.
Its been almost seven years since I was diagnosed with bone marrow cancer. I’ve been receiving ongoing treatment ever since.
Anna Edney’s Washington Post article about the high cost of cancer drugs doesn’t have anything to do with the sequester. This is an ongoing challenge for many of us:
I am flying-off to Illinios today to cover the American Society of Clinical Oncology (ASCO) meetings in Chicago. Here is a summary of some of the exciting cancer therapy related news we can expect to learn about there this weekend: